Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease

Keli L. Hippen, Ethan G. Aguilar, Stephanie Y. Rhee, Sara Bolivar-Wagers, Bruce R. Blazar

Research output: Contribution to journalReview article

Abstract

Despite graft-versus-host disease (GVHD) prophylactic agents, the success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD. Increasing donor graft regulatory T cell (Treg):effector T cell (Teff) ratios can substantially reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging inflammatory environment for Treg stability, persistence, and function. Metabolism plays a crucial role in T cell and Treg differentiation, and development of effector function. Although glycolysis is a main driver of allogeneic T cell-driven GVHD, oxidative phosphorylation is a main driver of Treg suppressor function. This review focuses on recent advances in our understanding of Treg metabolism in the context of GVHD, and discusses potential therapeutic applications of Tregs in the prevention or treatment of GVHD in cancer patients.

Original languageEnglish (US)
Pages (from-to)77-91
Number of pages15
JournalTrends in Immunology
Volume41
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Graft vs Host Disease
Regulatory T-Lymphocytes
T-Lymphocytes
Eragrostis
Hematopoietic Stem Cell Transplantation
Oxidative Phosphorylation
Glycolysis
Cell Differentiation
Neoplasms
Tissue Donors
Transplants
Therapeutics

Keywords

  • Foxp3
  • GVHD
  • OXPHOS
  • Treg
  • glycolysis
  • microbiota

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. / Hippen, Keli L.; Aguilar, Ethan G.; Rhee, Stephanie Y.; Bolivar-Wagers, Sara; Blazar, Bruce R.

In: Trends in Immunology, Vol. 41, No. 1, 01.2020, p. 77-91.

Research output: Contribution to journalReview article

Hippen, Keli L. ; Aguilar, Ethan G. ; Rhee, Stephanie Y. ; Bolivar-Wagers, Sara ; Blazar, Bruce R. / Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease. In: Trends in Immunology. 2020 ; Vol. 41, No. 1. pp. 77-91.
@article{f0268cc57b7747eca264c76c92e5a414,
title = "Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease",
abstract = "Despite graft-versus-host disease (GVHD) prophylactic agents, the success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD. Increasing donor graft regulatory T cell (Treg):effector T cell (Teff) ratios can substantially reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging inflammatory environment for Treg stability, persistence, and function. Metabolism plays a crucial role in T cell and Treg differentiation, and development of effector function. Although glycolysis is a main driver of allogeneic T cell-driven GVHD, oxidative phosphorylation is a main driver of Treg suppressor function. This review focuses on recent advances in our understanding of Treg metabolism in the context of GVHD, and discusses potential therapeutic applications of Tregs in the prevention or treatment of GVHD in cancer patients.",
keywords = "Foxp3, GVHD, OXPHOS, Treg, glycolysis, microbiota",
author = "Hippen, {Keli L.} and Aguilar, {Ethan G.} and Rhee, {Stephanie Y.} and Sara Bolivar-Wagers and Blazar, {Bruce R.}",
year = "2020",
month = "1",
doi = "10.1016/j.it.2019.11.005",
language = "English (US)",
volume = "41",
pages = "77--91",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Distinct Regulatory and Effector T Cell Metabolic Demands during Graft-Versus-Host Disease

AU - Hippen, Keli L.

AU - Aguilar, Ethan G.

AU - Rhee, Stephanie Y.

AU - Bolivar-Wagers, Sara

AU - Blazar, Bruce R.

PY - 2020/1

Y1 - 2020/1

N2 - Despite graft-versus-host disease (GVHD) prophylactic agents, the success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD. Increasing donor graft regulatory T cell (Treg):effector T cell (Teff) ratios can substantially reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging inflammatory environment for Treg stability, persistence, and function. Metabolism plays a crucial role in T cell and Treg differentiation, and development of effector function. Although glycolysis is a main driver of allogeneic T cell-driven GVHD, oxidative phosphorylation is a main driver of Treg suppressor function. This review focuses on recent advances in our understanding of Treg metabolism in the context of GVHD, and discusses potential therapeutic applications of Tregs in the prevention or treatment of GVHD in cancer patients.

AB - Despite graft-versus-host disease (GVHD) prophylactic agents, the success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD. Increasing donor graft regulatory T cell (Treg):effector T cell (Teff) ratios can substantially reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging inflammatory environment for Treg stability, persistence, and function. Metabolism plays a crucial role in T cell and Treg differentiation, and development of effector function. Although glycolysis is a main driver of allogeneic T cell-driven GVHD, oxidative phosphorylation is a main driver of Treg suppressor function. This review focuses on recent advances in our understanding of Treg metabolism in the context of GVHD, and discusses potential therapeutic applications of Tregs in the prevention or treatment of GVHD in cancer patients.

KW - Foxp3

KW - GVHD

KW - OXPHOS

KW - Treg

KW - glycolysis

KW - microbiota

UR - http://www.scopus.com/inward/record.url?scp=85076459788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076459788&partnerID=8YFLogxK

U2 - 10.1016/j.it.2019.11.005

DO - 10.1016/j.it.2019.11.005

M3 - Review article

C2 - 31791718

AN - SCOPUS:85076459788

VL - 41

SP - 77

EP - 91

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 1

ER -